LECLANCHE SA header image

LECLANCHE SA

LECN

Equity

ISIN CH0110303119 / Valor 11030311

SIX Swiss Exchange (2024-11-21)
CHF 0.16-3.06%

LECLANCHE SA
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Leclanché SA is a leading provider of energy storage solutions specializing in lithium-ion cell technology. The company's EMS software suite is designed to manage large grid-connected battery energy storage systems, with a focus on integrating multiple battery/inverter combinations. Leclanché also offers Build-Own-Operate projects for Stationary Solutions with long-term power purchase agreements. The company's core operating units include Stationary Solutions, e-Transport Solutions, and Special Battery Systems, providing benefits to grid operators, utilities, and commercial energy users. With over 100 years of battery innovation, Leclanché manufactures its own cells to develop custom-designed solutions for customers, as well as specifying third-party cells when necessary. The company is reorganizing to become a green tech software and systems integration company with expanded production and R&D capabilities, aiming to accelerate progress towards a cleaner energy future.

Summarized from source with an LLMView SourceSector: Technology

Latest Results (20.08.2024):

Income Growth

In H1 2023, Leclanché SA reported a consolidated income of CHF 8.9 million, marking a significant increase of approximately 17% compared to CHF 7.6 million in the same period of 2022. This growth is attributed to the successful expansion and execution of customer orders in the strategic focus areas of marine, rail, and specialized trucks.

EBITDA Improvement

The EBITDA loss for the first half of 2023 amounted to CHF (27.0) million, showcasing an improvement from CHF (34.1) million the previous year. This reflects the company's ongoing efforts in capital expenditure and strategic investments aimed at future growth.

Net Loss Reduction

Despite a net loss of CHF (37.3) million in the first half of 2023, Leclanché SA managed to reduce its net loss by 20% compared to the same period in 2022. This reduction is a result of the company's strategic refocusing and operational efficiency improvements under new management.

Balance Sheet Strengthening

Leclanché SA's balance sheet totaled CHF 105.5 million as of June 30, 2023, compared to CHF 90.8 million on December 31, 2022. This improvement is due to a strategic move to convert CHF 66.7 million in debt into equity through a capital increase, mitigating the negative equity situation from the previous year.

Revenue from E-Mobility Segment

In H1 2023, Leclanché SA's E-Mobility segment secured major partnerships for electric and hybrid ferries, contributing to overall revenue growth. Noteworthy repeat orders from key players like Alstom Rail and Canadian Pacific Kansas City further enhanced revenue streams and market recognition.

Summarized from source with an LLMView Source

Key figures

-60.4%1Y
-75.3%3Y
-87.1%5Y

Performance

149%1Y
99.9%3Y
91.1%5Y

Volatility

Market cap

143 M

Market cap (USD)

Daily traded volume (Shares)

120,194

Daily traded volume (Shares)

1 day high/low

0.164 / 0.15

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Pacific Biosciences of California Inc
Pacific Biosciences of California Inc Pacific Biosciences of California Inc Valor: 11661709
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.91%USD 1.77
JOYY Inc
JOYY Inc JOYY Inc Valor: 51728275
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.25%USD 36.03
Relay Therapeutics Inc
Relay Therapeutics Inc Relay Therapeutics Inc Valor: 55675918
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.43%USD 4.64
Alarm.com Holdings Inc
Alarm.com Holdings Inc Alarm.com Holdings Inc Valor: 28367881
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.96%USD 60.78
Xerox Holdings Corporation
Xerox Holdings Corporation Xerox Holdings Corporation Valor: 49153526
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.29%USD 8.75
Plexus Corp
Plexus Corp Plexus Corp Valor: 963299
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.90%USD 159.63
Tandem Diabetes Care Inc
Tandem Diabetes Care Inc Tandem Diabetes Care Inc Valor: 38586336
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.96%USD 30.74
Itron Inc
Itron Inc Itron Inc Valor: 941538
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.98%USD 116.37
Viavi Solutions Inc
Viavi Solutions Inc Viavi Solutions Inc Valor: 29031946
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.81%USD 9.90
Credo Technology Group Holding Limited
Credo Technology Group Holding Limited Credo Technology Group Holding Limited Valor: 116145651
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
7.70%USD 46.28